Dermalogica launched its Exo Booster, a bacterial, pro-resolution technology combined with a vegan exosome complex containing approximately 10 billion Lactobacillus exosomes in each application, according to a Jan. 10 announcement.
Dermalogica launched its Exo Booster, a bacterial, pro-resolution technology combined with a vegan exosome complex containing approximately 10 billion Lactobacillus exosomes in each application, according to a Jan. 10 announcement.
The Exo Booster is an addition to Dermilogica’s “pro-treatment” line for redefining post-treatment recovery and skin rejuvenation, a human micro-biome derived exosome treatment for skin recovery after micro injury treatment.
The clinical studies Dermilogica conducted for the product 21 days post treatment concluded that 86% of users experienced greater wrinkle reduction and 46% saw a boost in skin resilience post-procedure.
The Exo Booster’s Lactobacillus exosomes promote cell renewal, while its Pro-Resolution Technology combines omega-3 and Bacillus ferment to repair and strengthen the skin barrier. Its peptides and olive phospholipids target elasticity and firmness.
Bob Bianchini, Ph.D., the vice president of research and development at Dermalogica says traditional exosome treatments use a variety of human-derived exosomes in regenerative and aesthetic medicine which can be problematic for certain patient populations.
"Our exosome treatment is combined with our pro-resolution technology which provides for a superior treatment experience because it is enriched with Omega-3’s from Algae, Vitamins, mushroom extract, Oligo peptide-1, olive oil phospholipoids and beta glucanes which combine to improve recovery time and micro injury treatment resolution,” Bianchini says.
